Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Global Health Ventures, a specialty pharmaceutical company focused on sublingual (under the tongue) drug delivery, has completed research on the development of its second drug, Relax-B, for anxiety attacks.
Subscribe to our email newsletter
Global Health said Relax-B is the sublingual formulation of Propranolol currently marketed for hypertension and it has decided to develop a rapid absorption formulation using their proprietary sublingual technology.
Further, the company had engaged a third party company to conduct a side by side study of Relax-B with Propranolol to compare dissolution and bioavailability.
The study was conducted under USP protocol and is now completed.It showed Relax-B to be 5 times (500%) faster/quicker in dissolution and bioavailability than the oral Propranolol.
The study result suggested the less utility of the drug and achieve faster and more effective results.
The drug shall now move to the clinical production and the company is planning to initiate human clinical trials in 2011.
Global Health president and CEO Hassan Salari said that they are very pleased with the results of their second drug Relax-B.
"We are now confident that our technology shall apply to a vast number of drugs that can bypass the gastrointestinal and liver side effects and result in faster onset of action," Salari said.